Anti-BCMA-Anti-CD19-Anti-CD3 Trispecific Molecule
This product is for research use only. It is not suitable for human diagnostic or therapeutic use. The anti-BCMA-anti CD19-anti-CD3 can be used for studying BCMA+ cancer cell-mediated T cell activatio
BiTE, variable regions only
- Data sheet: View or download
- Related Content: CAR-T research tools
The Anti-BCMA-Anti-CD19-Anti-CD3-His Trispecific Antibody is engineered to bind to three different targets simultaneously: 1) BCMA, a B cell antigen that is highly expressed by mature B cells and malignant myeloma cells, 2) CD19, a B-cell marker that is a target for many leukemias and lymphomas, and 3) CD3, a T cell receptor activation signal that leads to cytokine secretion. The multi-functionality of this trispecific antibody allows it to bind to BCMA and CD19 on the tumor cell and CD3 on T cells simultaneously, thus bringing T lymphocytes closer to the cancer cells. The binding event targets the tumor while providing co-stimulatory signals that promote T cell expansion and cytotoxicity against BCMA+ and CD19+ cancer cells.
Stable for at least 12 months at -80°C. Avoid freeze/thaw cycles.